Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;4(5):295-306.
doi: 10.2217/cns.15.28. Epub 2015 Nov 6.

Molecular diagnostics: techniques and recommendations for 1p/19q assessment

Affiliations
Review

Molecular diagnostics: techniques and recommendations for 1p/19q assessment

Adelheid Woehrer et al. CNS Oncol. 2015.

Abstract

Several morphology- and polymerase chain reaction (PCR)-based methods for chromosome 1p 19q deletion status assessment are available. Important prerequisites for all molecular techniques concern tissue quality and selection of regions of interest. The most common methods for diagnostic 1p 19q assessment are fluorescence in situ hybridization and PCR-based microsatellite analysis. While the latter requires the use of autologous blood samples, more advanced techniques such as array comparative genomic hybridization, multiplex ligation-dependent probe amplification or real-time PCR are independent from autologous DNA samples. However, due to high technical demand and experience required their applicability as diagnostic tests remains to be shown. On the other hand, chromogenic in situ hybridization evolves as attractive alternative to FISH. Herein, the available test methods are reviewed and outlined, their advantages and drawbacks being discussed in detail.

Keywords: 1p 19q deletion; analytical performance; clinical performance; oligodendroglial tumors.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Evaluated regions on chromosome 1.
aCGH: Array comparative genomic hybridization; CISH: Chromogenic in situ hybridization; LOH: Loss of heterozygosity; MLPA: Multiplex ligation-dependent probe amplification.
<b>Figure 2.</b>
Figure 2.. Evaluated regions on chromosome 19.
aCGH: Array comparative genomic hybridization; CISH: Chromogenic in situ hybridization; LOH: Loss of heterozygosity; MLPA: Multiplex ligation-dependent probe amplification.
<b>Figure 3.</b>
Figure 3.. Representative 1p 19q FISH images.
Target signal: red; control signal: green; DAPI counterstained. (A) Normal diploid signal ratio (2 controls/2 targets), magnification 63×. (B) Deletion status (signal ratio 2 controls/1 target), magnification 63×. (C) Imbalance with relative loss (4 control/2 target signals), magnification 63×. (D) FISH on a 4-micron-thick tissue section (magnification 40×) displaying a case with deletion status (signal ratio 2 controls/1 target) of the majority of nuclei.

References

    1. Berghoff AS, Stefanits H, Woehrer A, Heinzl H, Preusser M, Hainfellner JA. Clinical neuropathology practice guide 3–2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers. Clin. Neuropathol. 2013;32(3):148–158. - PMC - PubMed
    1. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–1812. - PMC - PubMed
    1. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673–8677. - PMC - PubMed
    1. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005;352(10):997–1003. - PubMed
    1. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 1998;90(19):1473–1479. - PubMed

MeSH terms

LinkOut - more resources